FAQ on Calidi Biotherapeutics Inc.'s 2025 Pipeline Progress and Strategic Focus

What is Calidi Biotherapeutics Inc. focusing on in 2025?

Calidi Biotherapeutics is focusing on advancing its RedTail platform and strategic pipeline, including IND-enabling studies for CLD-401 and opening an IND for CLD-201, with Phase I trials anticipated by year-end.

Who are the key executives mentioned in the shareholder letter?

The shareholder letter mentions CEO Eric Poma, PhD, appointed in April 2025, and Dr. Guy Travis Clifton as the Chief Medical Officer.

What is the RedTail platform?

The RedTail platform is a systemically delivered virotherapy designed by Calidi Biotherapeutics to target metastatic cancers and deliver genetic payloads, showcasing tumor selectivity and immune modulation potential in preclinical data.

What are CLD-401 and CLD-201?

CLD-401 is Calidi’s lead candidate with IND-enabling studies underway, expected to file by end of 2026. CLD-201 is an intratumoral virotherapy with an IND opened and Phase I trials anticipated by year-end.

How is Calidi Biotherapeutics financially positioned?

Calidi ended Q1 with $10.6 million in cash and a significantly reduced burn rate, aiming to rapidly advance its pipeline while enhancing shareholder value.

Where can I find more information about Calidi Biotherapeutics?

More information is available on the company’s website at www.calidibio.com and in the company’s newsroom at https://ibn.fm/CLDI.

What are the implications of Calidi’s advancements for cancer treatment?

Calidi’s advancements, particularly the RedTail platform and its virotherapies, aim to enhance efficacy and improve patient safety in treating metastatic cancers and solid tumors, potentially preventing metastatic disease.

When are the Phase I trials for CLD-201 expected to begin?

Phase I trials for CLD-201 are anticipated to begin by the end of the year.

What is the significance of the preclinical data presented at AACR and ASCO?

The preclinical data showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and advancing IND-enabling studies for lead candidate CLD-401.